MYC and plasma cell myeloma: We have recently demonstrated through in vitro and in vivo studies that the more effective methylated form, PRIMA-1Met, can display a potent anti-myeloma activity without requiring functional activation of p53, which is associated with activation of p63/73 signaling pathway and down-regulation of c-Myc [9].